CheckMan Stock Market Overview
Trending Stocks
Red List
In Today's Headlines
Data centers have gotten so large that their power demands now rival entire U.S. states. Take Meta's Hyperion AI data center, for example.
NERA's rating downgrade reflects rising cost pressures, softer leasing trends and higher vacancies, even as acquisitions and steady distributions provide some support to the near-term outlook.
GE Aerospace ramps up significant investments in MRO and manufacturing, aiming to boost capacity, cut turnaround times and support strong engine demand.
Shares of NVIDIA Corporation moved higher on Wednesday, rising as much as 1.67% before paring gains to trade about 0.6% higher. The advance came after the chipmaker closed the first quarter on a stronger note, even as it logged its second consecutive quarterly decline.
The high-profile executive was a key figure in the company's expansion into fitness technology and services.
SolarEdge Technologies, Inc. (SEDG) Discusses Solid-State Transformers and Infrastructure Solutions for AI Data Centers Transcript
SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against PayPal Holdings, Inc. (NASDAQ: PYPL) and certain of its top executives. The litigation follows a surprise leadership change and the sudden withdrawal of long-term financial targets that had been a cornerstone of the company's growth narrative.
IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.
SYPR swings to a Q4 loss per share as the Technologies segment slumps, overshadowing Electronics growth, while tariffs and supply chain challenges pressure margins. Yet, rising orders provide some respite.
SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials.